222(top 1%)
PR articles
84.6K(top 0.1%)
PR citations
58(top 1%)
PR h-index
65(top 1%)
h-index
296
documents
101.7K
doc citations
10.0K
citing journals
100
times ranked

Publications

235 peer-reviewed articles • 94,933 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation in Relation to Time in Therapeutic Range: An Analysis of US Food and Drug Administration Regulatory Data
Circulation: Cardiovascular Quality and Outcomes, 2025, 18,
4.10Citations (PDF)
2Interventions to help patients withdraw from depression drugs: A systematic review
International Journal of Risk and Safety in Medicine, 2024, 35, 103-116
0.68Citations (PDF)
3Systematic violations of patients’ rights and safety: forced medication of a cohort of 30 patients in Alaska
Psychosis, 2023, 15, 145-154
1.01Citations (PDF)
4Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents
Journal of Clinical Epidemiology, 2022, 143, 242-253
3.73Citations (PDF)
5Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
The Cochrane Library, 2022, 2022,
2.114Citations (PDF)
6Made in China: the coronavirus that killed millions of people
Indian Journal of Medical Ethics, 2022, 7, 254-254
0.64Citations (PDF)
7Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: A case study of public documents: author's reply
Journal of Clinical Epidemiology, 2022, 145, 183-184
3.71Citations (PDF)
8Restoring the two pivotal fluoxetine trials in children and adolescents with depression
International Journal of Risk and Safety in Medicine, 2022, 33, 385-408
0.66Citations (PDF)
9House dust mite control measures for asthma
The Cochrane Library, 2021, 2021,
2.126Citations (PDF)
10Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
The Cochrane Library, 2021, 2021,
2.112Citations (PDF)
11Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants
International Journal of Risk and Safety in Medicine, 2021, 32, 87-99
0.65Citations (PDF)
12Joint study led by International Food Policy Research Institute (IFPRI) puts meat-eating women’s lives at risk
Indian Journal of Medical Ethics, 2021, 06, 81-82
0.60Citations (PDF)
13Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs
Research Integrity and Peer Review, 2021, 6,
4.97Citations (PDF)
14Are investigators’ access to trial data and rights to publish restricted and are potential trial participants informed about this? A comparison of trial protocols and informed consent materials
BMC Medical Ethics, 2021, 22,
2.43Citations (PDF)
15Long-term use of antipsychotics and antidepressants is not evidence-based
International Journal of Risk and Safety in Medicine, 2020, 31, 37-42
0.67Citations (PDF)
16Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence
Npj Vaccines, 2020, 5,
5.33Citations (PDF)
17Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports
Systematic Reviews, 2020, 9,
4.729Citations (PDF)
18Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications
Systematic Reviews, 2020, 9,
4.75Citations (PDF)
19Presentation of benefits and harms of antidepressants on websites: A cross-sectional study
International Journal of Risk and Safety in Medicine, 2020, 31, 53-65
0.619Citations (PDF)
20Title is missing!
2020
2Citations (PDF)
21What have antidepressants been tested for? A systematic review
International Journal of Risk and Safety in Medicine, 2020, 31, 157-163
0.66Citations (PDF)
22Systematic violations of patients’ rights and safety: Forced medication of a cohort of 30 patients
Indian Journal of Medical Ethics, 2020, 05, 312-318
0.64Citations (PDF)
23Title is missing!
2020
0Citations (PDF)
24Effect of lithium on suicide and mortality in mood disorders: A systematic review
International Journal of Risk and Safety in Medicine, 2019, 30, 155-166
0.613Citations (PDF)
25Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports
International Journal of Risk and Safety in Medicine, 2019, 30, 217-232
0.615Citations (PDF)
26General health checks in adults for reducing morbidity and mortality from disease
The Cochrane Library, 2019, 2019,
2.1113Citations (PDF)
27Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review
International Journal of Risk and Safety in Medicine, 2019, 30, 193-201
0.68Citations (PDF)
28Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review
International Journal of Risk and Safety in Medicine, 2019, 30, 59-71
0.610Citations (PDF)
29Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols
BMJ Open, 2019, 9, e026661
1.910Citations (PDF)
30Screening for reducing morbidity and mortality in malignant melanoma
The Cochrane Library, 2019, 2019,
2.160Citations (PDF)
31What is the moral collapse in the Cochrane Collaboration about?
Indian Journal of Medical Ethics, 2019, IV, 303-309
0.61Citations (PDF)
32Redactions in protocols for drug trials: what industry sponsors concealed
Journal of the Royal Society of Medicine, 2018, 111, 136-141
1.812Citations (PDF)
33A totally new system is needed for drug research and development
European Journal of Clinical Investigation, 2018, 48,
3.05Citations (PDF)
34Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review
Systematic Reviews, 2018, 7,
4.724Citations (PDF)
35Routine versus selective antifungal administration for control of fungal infections in patients with cancer
The Cochrane Library, 2017, 2017,
2.115Citations (PDF)
36Nystatin prophylaxis and treatment in severely immunodepressed patients
The Cochrane Library, 2017, 2017,
2.130Citations (PDF)
37Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients
The Cochrane Library, 2017, 2017,
2.110Citations (PDF)
38Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
The Cochrane Library, 2017, 2017,
2.116Citations (PDF)
39Breast Cancer Screening in Denmark
Annals of Internal Medicine, 2017, 166, 313-323
9.6113Citations (PDF)
40Patients should have free and immediate access to all information related to clinical trials
BMJ: British Medical Journal, 2017, , j1221
0.11Citations (PDF)
41Breast Cancer Screening in Denmark
Annals of Internal Medicine, 2017, 167, 524
9.65Citations (PDF)
42Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review
Journal of the Royal Society of Medicine, 2017, 110, 404-410
1.871Citations (PDF)
43The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder
Evidence-Based Medicine, 2017, 22, 143-147
0.818Citations (PDF)
44The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials
Journal of Clinical Epidemiology, 2017, 91, 129-136
3.718Citations (PDF)
45Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports
Cmaj, 2017, 189, E194-E203
1.269Citations (PDF)
46Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies
International Journal of Risk and Safety in Medicine, 2017, 29, 107-124
0.68Citations (PDF)
47Hvad ved vi om sikkerheden af HPV-vaccinerne?
Tidsskrift for Den Norske Laegeforening, 2017, 137, 11-12
0.11Citations (PDF)
48Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis
PLoS Medicine, 2016, 13, e1002101
8.062Citations (PDF)
49Author’s reply to Dubicka and colleagues and Stone
BMJ, The, 2016, , i915
0.21Citations (PDF)
50Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease
The Cochrane Library, 2016, 2016,
2.146Citations (PDF)
51Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers
Journal of the Royal Society of Medicine, 2016, 109, 381-392
1.848Citations (PDF)
52Screening with urinary dipsticks for reducing morbidity and mortality
The Cochrane Library, 2015, 2015,
2.121Citations (PDF)
53Under-reporting of conflicts of interest among trialists: a cross-sectional study
Journal of the Royal Society of Medicine, 2015, 108, 101-107
1.839Citations (PDF)
54Does long term use of psychiatric drugs cause more harm than good?
BMJ, The, 2015, 350, h2435-h2435
0.275Citations (PDF)
55Influence of mammography screening on use of mastectomies in Denmark
Acta Oncológica, 2015, 54, 133-134
1.83Citations (PDF)
56Author's reply to Tovey and colleagues
BMJ, The, 2015, 350, h2955-h2955
0.21Citations (PDF)
57Mammography screening is harmful and should be abandoned
Journal of the Royal Society of Medicine, 2015, 108, 341-345
1.842Citations (PDF)
58Comment on “Our prescription drugs kill us in large numbers”. Author's reply
Polish Archives of Internal Medicine, 2015, 125, 106-107
0.60Citations (PDF)
59Comparison of Results from Different Imputation Techniques for Missing Data from an Anti-Obesity Drug Trial
PLoS ONE, 2014, 9, e111964
2.338Citations (PDF)
60"Human guinea pig" asks for animal studies
BMJ, The, 2014, 349, g6714-g6714
0.27Citations (PDF)
61Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study
BMJ, The, 2014, 348, g3555-g3555
0.211Citations (PDF)
62Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications
BMJ, The, 2014, 348, g3510-g3510
0.260Citations (PDF)
63Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration
International Journal of Surgery, 2014, 12, 1500-1524
5.42,636Citations (PDF)
64Study of study of changes in antidepressant use after FDA warnings is not reliable
BMJ, The, 2014, 349, g5623-g5623
0.21Citations (PDF)
65Muscular adverse effects are common with statins
BMJ, The, 2014, 348, g3724-g3724
0.23Citations (PDF)
66Increasing value and reducing waste: addressing inaccessible research
Lancet, The, 2014, 383, 257-266
62.1794Citations (PDF)
67Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin
BMJ, The, 2014, 349, g4790-g4790
0.21Citations (PDF)
68Our prescription drugs kill us in large numbers
Polish Archives of Internal Medicine, 2014, 124, 628-634
0.616Citations (PDF)
69Re: Et korstog mot legemiddelindustrien
Tidsskrift for Den Norske Laegeforening, 2014, 134, 2126-2127
0.10Citations (PDF)
70Przepisywane leki przyczyną zgonu rzeszy pacjentów
Polish Archives of Internal Medicine, 2014, 124, 750-756
0.60Citations (PDF)
71Strategies for obtaining unpublished drug trial data: a qualitative interview study
Systematic Reviews, 2013, 2,
4.724Citations (PDF)
72Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study
BMC Medical Ethics, 2013, 14,
2.484Citations (PDF)
73Developing a new drug costs less than $100m, not $900m
BMJ, The, 2013, 346, f398-f398
0.22Citations (PDF)
74Screening for breast cancer with mammography
The Cochrane Library, 2013, 2013,
2.1816Citations (PDF)
75AbbVie considers harms to be commercially confidential information: sign a petition
BMJ, The, 2013, 347, f7569-f7569
0.21Citations (PDF)
76Universal health checks should be abandoned
BMJ, The, 2013, 347, f5227-f5227
0.216Citations (PDF)
77Citations of scientific results and conflicts of interest: the case of mammography screening
Evidence-Based Medicine, 2013, 18, 83-89
0.819Citations (PDF)
78Roche continues to drag its feet on access to Tamiflu data
BMJ, The, 2013, 346, f3001-f3001
0.21Citations (PDF)
79Searching for unpublished data for Cochrane reviews: cross sectional study
BMJ, The, 2013, 346, f2231-f2231
0.243Citations (PDF)
80General Health Checks in Adults for Reducing Morbidity and Mortality From Disease
JAMA - Journal of the American Medical Association, 2013, 309, 2489
16.541Citations (PDF)
81SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
BMJ, The, 2013, 346, e7586-e7586
0.24,990Citations (PDF)
82Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react?
International Journal of Risk and Safety in Medicine, 2013, 25, 155-168
0.65Citations (PDF)
83Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis
British Journal of Cancer, 2013, 109, 2014-2019
5.590Citations (PDF)
84The Two-County Breast Screening Trial Cannot Provide a Reliable Estimate of the Effect of Breast Cancer Screening
Radiology, 2012, 262, 729-730
8.73Citations (PDF)
85General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis
BMJ, The, 2012, 345, e7191-e7191
0.2276Citations (PDF)
86Why does the BMJ support donations of pulse oximeters when they have no effect?
BMJ: British Medical Journal, 2012, 344, e409-e409
0.11Citations (PDF)
87Income from reprints creates a conflict of interests
BMJ, The, 2012, 345, e4970-e4970
0.21Citations (PDF)
88Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses?
BMJ, The, 2012, 345, e7031-e7031
0.282Citations (PDF)
89European governments should sue Roche and prescribers should boycott its drugs
BMJ, The, 2012, 345, e7689-e7689
0.26Citations (PDF)
90Deficiencies in proposed new EU regulation of clinical trials
BMJ, The, 2012, 345, e8522-e8522
0.216Citations (PDF)
91Big pharma often commits corporate crime, and this must be stopped
BMJ, The, 2012, 345, e8462-e8462
0.217Citations (PDF)
92CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials
International Journal of Surgery, 2012, 10, 28-55
5.42,054Citations (PDF)
93Sponsors’ participation in conduct and reporting of industry trials: a descriptive study
Trials, 2012, 13,
2.048Citations (PDF)
94Challenges in Coding Adverse Events in Clinical Trials: A Systematic Review
PLoS ONE, 2012, 7, e41174
2.370Citations (PDF)
95What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re‐uptake inhibitors
Addiction, 2012, 107, 900-908
5.293Citations (PDF)
96Regular Health Checks: Cross-Sectional Survey
PLoS ONE, 2012, 7, e33694
2.39Citations (PDF)
97Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study
Lancet Oncology, The, 2011, 12, 1118-1124
27.490Citations (PDF)
98Why we need easy access to all data from all clinical trials and how to accomplish it
Trials, 2011, 12,
2.0122Citations (PDF)
99Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study
BMC Medical Research Methodology, 2011, 11,
2.5190Citations (PDF)
100Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data
BMJ: British Medical Journal, 2011, 343, d4692-d4692
0.146Citations (PDF)
101Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study
BMJ: British Medical Journal, 2011, 343, d4829-d4829
0.156Citations (PDF)
102Opening up data at the European Medicines Agency
BMJ: British Medical Journal, 2011, 342, d2686-d2686
0.194Citations (PDF)
103The Breast Screening Programme and misinforming the public
Journal of the Royal Society of Medicine, 2011, 104, 361-369
1.837Citations (PDF)
104Niels Finsen's treatment for lupus vulgaris
Journal of the Royal Society of Medicine, 2011, 104, 41-42
1.838Citations (PDF)
105UK drug regulator destroys all evidence after 15 years
BMJ: British Medical Journal, 2011, 343, d4203-d4203
0.12Citations (PDF)
106The proposed review will not be independent without NICE
BMJ: British Medical Journal, 2011, 343, d7533-d7533
0.10Citations (PDF)
107The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
BMJ: British Medical Journal, 2011, 343, d5928-d5928
0.130,272Citations (PDF)
108Time to stop mammography screening?
Cmaj, 2011, 183, 1957-1958
1.238Citations (PDF)
109Why mammography screening has not lived up to expectations from the randomised trials
Cancer Causes and Control, 2011, 23, 15-21
1.762Citations (PDF)
110Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review
BMJ: British Medical Journal, 2010, 341, c3920-c3920
0.1338Citations (PDF)
111The Background Review for the USPSTF Recommendation on Screening for Breast Cancer
Annals of Internal Medicine, 2010, 152, 538
9.64Citations (PDF)
112CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
BMJ: British Medical Journal, 2010, 340, c869-c869
0.16,574Citations (PDF)
113Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study
BMJ: British Medical Journal, 2010, 341, c3926-c3926
0.127Citations (PDF)
114Acupuncture Treatment for Pain: Systematic Review of Randomised Clinical Trials with Acupuncture, Placebo Acupuncture, and no Acupuncture Groups
Deutsche Zeitschrift Für Akupunktur, 2010, 53, 40-41
0.02Citations (PDF)
115Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study
BMJ: British Medical Journal, 2010, 341, c3653-c3653
0.152Citations (PDF)
116Breast screening: why estimates differ by a factor of 20-25
Journal of Medical Screening, 2010, 17, 158-159
2.08Citations (PDF)
117Who evaluates public health programmes? A review of the NHS Breast Screening Programme
Journal of the Royal Society of Medicine, 2010, 103, 14-20
1.817Citations (PDF)
118Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study
PLoS Medicine, 2010, 7, e1000354
8.0107Citations (PDF)
119Breast cancer mortality in organised mammography screening in Denmark: comparative study
BMJ: British Medical Journal, 2010, 340, c1241-c1241
0.1172Citations (PDF)
120Sleep apnoea: from person to patient, and back again
BMJ: British Medical Journal, 2010, 340, c360-c360
0.11Citations (PDF)
121CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
Journal of Clinical Epidemiology, 2010, 63, e1-e37
3.71,702Citations (PDF)
122Still awaiting screening facts
BMJ: British Medical Journal, 2010, 341, c6152-c6152
0.117Citations (PDF)
123The benefits and harms of screening for cancer with a focus on breast screening
Polish Archives of Internal Medicine, 2010, 120, 89-94
0.647Citations (PDF)
124What Should Be Done To Tackle Ghostwriting in the Medical Literature?
PLoS Medicine, 2009, 6, e1000023
8.096Citations (PDF)
125Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends
BMJ: British Medical Journal, 2009, 339, b2587-b2587
0.1424Citations (PDF)
126Estimation of lead time and overdiagnosis in breast cancer screening
British Journal of Cancer, 2009, 100, 219-219
5.518Citations (PDF)
127The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
BMJ: British Medical Journal, 2009, 339, b2700-b2700
0.116,310Citations (PDF)
128Alpha 1-Antitrypsin Deficiency
New England Journal of Medicine, 2009, 361, 2101-2102
34.51Citations (PDF)
129Informed choice requires information about both benefits and harms
Journal of Medical Ethics, 2009, 35, 268-269
2.345Citations (PDF)
130The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
PLoS Medicine, 2009, 6, e1000100
8.015,719Citations (PDF)
131Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention
BMC Medical Research Methodology, 2009, 9,
2.5338Citations (PDF)
132Mejorar la comunicación de estudios observacionales en epidemiología (STROBE): explicación y elaboración
Gaceta Sanitaria, 2009, 23, 158.e1-158.e28
1.0168Citations (PDF)
133Overdiagnosis in organised mammography screening in Denmark. A comparative study
BMC Women's Health, 2009, 9,
2.482Citations (PDF)
134Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason
Journal of Negative Results in BioMedicine, 2009, 8,
1.610Citations (PDF)
135Readers as research detectives
Trials, 2009, 10,
2.08Citations (PDF)
136Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory
Journal of Clinical Epidemiology, 2009, 62, 967-973
3.746Citations (PDF)
137The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Journal of Clinical Epidemiology, 2009, 62, e1-e34
3.710,120Citations (PDF)
138Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups
BMJ: British Medical Journal, 2009, 338, a3115-a3115
0.1333Citations (PDF)
139Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study
BMJ: British Medical Journal, 2009, 339, b3128-b3128
0.174Citations (PDF)
140A cause for celebration, and caution
BMJ: British Medical Journal, 2009, 338, b2126-b2126
0.15Citations (PDF)
141Fundamental errors in estimate of lives saved by screening
BMJ: British Medical Journal, 2009, 339, b3359-b3359
0.13Citations (PDF)
142Breast screening: the facts--or maybe not
BMJ: British Medical Journal, 2009, 338, b86-b86
0.1130Citations (PDF)
143Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies
BMC Medical Research Methodology, 2008, 8,
2.5313Citations (PDF)
144Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions
BMC Medical Research Methodology, 2008, 8,
2.567Citations (PDF)
145Biases in estimates of overdetection due to mammography screening
Lancet Oncology, The, 2008, 9, 199-201
27.415Citations (PDF)
146Topical NSAIDs have unknown effectiveness
BMJ: British Medical Journal, 2008, 336, 344.3-344
0.11Citations (PDF)
147Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols
BMJ: British Medical Journal, 2008, 337, a2299-a2299
0.1175Citations (PDF)
148Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials
International Journal of Epidemiology, 2007, 36, 847-857
4.9417Citations (PDF)
149Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
PLoS Medicine, 2007, 4, e297
8.05,250Citations (PDF)
150Ghost Authorship in Industry-Initiated Randomised Trials
PLoS Medicine, 2007, 4, e19
8.0245Citations (PDF)
151Data Extraction Errors in Meta-analyses That Use Standardized Mean Differences
JAMA - Journal of the American Medical Association, 2007, 298,
16.5183Citations (PDF)
152Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
Epidemiology, 2007, 18, 805-835
2.82,541Citations (PDF)
153Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study
BMC Medicine, 2007, 5,
7.144Citations (PDF)
154Believability of relative risks and odds ratios in abstracts: cross sectional study
BMJ: British Medical Journal, 2006, 333, 231-234
0.178Citations (PDF)
155Were Patients With Unfavorable Outcomes Deleted in a Covert Duplicate Publication Reporting Effect of Placebo on Hypertension?
American Journal of Hypertension, 2006, 19, 655-655
2.00Citations (PDF)
156Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies
Journal of Clinical Epidemiology, 2006, 59, 336-338
3.740Citations (PDF)
157Follow-up Commentary
Journal of Clinical Epidemiology, 2006, 59, 340-341
3.71Citations (PDF)
158Authors' reply on Cochrane reviews v industry supported meta-analyses
BMJ: British Medical Journal, 2006, 333, 1072.4-1073
0.10Citations (PDF)
159Laser and photoepilation for unwanted hair growth
The Cochrane Library, 2006, ,
2.167Citations (PDF)
160Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations
Trials, 2006, 7,
2.012Citations (PDF)
161Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents
BMC Medical Research Methodology, 2006, 6,
2.53Citations (PDF)
162Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden
International Journal of Cancer, 2006, 118, 2648-2648
4.32Citations (PDF)
163Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review
BMJ: British Medical Journal, 2006, 333, 782
0.1383Citations (PDF)
164Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics
European Journal of Cancer, 2006, ,
4.96Citations (PDF)
165Ramifications of screening for breast cancer: Overdiagnosis in the Malmö trial was considerably underestimated
BMJ: British Medical Journal, 2006, 332, 727.2
0.14Citations (PDF)
166Human Albumin in Critically Ill Patients
Critical Care Medicine, 2005, 33, 1183
0.54Citations (PDF)
167The Journal Impact Factor as a Predictor of Trial Quality and Outcomes: Cohort Study of Hepatobiliary Randomized Clinical Trials
American Journal of Gastroenterology, 2005, 100, 2431-2435
0.737Citations (PDF)
168Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study
BMJ: British Medical Journal, 2005, 330, 1049
0.1172Citations (PDF)
169Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis
The Cochrane Library, 2005, ,
2.157Citations (PDF)
170Reduction in mortality from breast cancer
BMJ: British Medical Journal, 2005, 330, 1024.3
0.11Citations (PDF)
171Model of outcomes of screening mammography: Information needs to support informed choices
BMJ: British Medical Journal, 2005, 331, 350.3-351
0.10Citations (PDF)
172Re: Trends in the Treatment of Ductal Carcinoma In Situ of the Breast
Journal of the National Cancer Institute, 2004, 96, 1257-1257
4.65Citations (PDF)
173Polyclonal Immunoglobulin for Treatment of Bacterial Sepsis: A Systematic Review
Clinical Infectious Diseases, 2004, 39, 38-46
5.2156Citations (PDF)
174Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials
JAMA - Journal of the American Medical Association, 2004, 291, 2457
16.51,649Citations (PDF)
175Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis
The Cochrane Library, 2004, ,
2.147Citations (PDF)
176Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study
BMJ: British Medical Journal, 2004, 328, 148-0
0.1124Citations (PDF)
177On the benefits and harms of screening for breast cancer
International Journal of Epidemiology, 2004, 33, 56-64
4.942Citations (PDF)
178The debate on breast cancer screening with mammography is important
Journal of the American College of Radiology, 2004, 1, 8-14
2.39Citations (PDF)
179Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Annals of Internal Medicine, 2004, 141, 781-788
9.61,379Citations (PDF)
180Websites on screening for breast cancer:Authors' reply
BMJ: British Medical Journal, 2004, 328, 769.5
0.10Citations (PDF)
181Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms
Pain, 2003, 104, 714-715
4.214Citations (PDF)
182Regular self-examination or clinical examination for early detection of breast cancer
The Cochrane Library, 2003, ,
2.1222Citations (PDF)
183Screening for Breast Cancer
Annals of Internal Medicine, 2003, 138, 769-770
9.61Citations (PDF)
184Prevalence of Honorary and Ghost Authorship in Cochrane Reviews
JAMA - Journal of the American Medical Association, 2002, 287, 2769
16.5199Citations (PDF)
185Trends in breast-conserving surgery in the Southeast Netherlands
European Journal of Cancer, 2002, 38, 1288
4.98Citations (PDF)
186Is the Placebo Powerless?
New England Journal of Medicine, 2001, 344, 1594-1602
34.51,481Citations (PDF)
187Cochrane review on screening for breast cancer with mammography
Lancet, The, 2001, 358, 1340-1342
62.1675Citations (PDF)
188Quality of Cochrane reviews: assessment of sample from 1998
BMJ: British Medical Journal, 2001, 323, 829-832
0.1138Citations (PDF)
189Debate on screening for breast cancer is not over
BMJ: British Medical Journal, 2001, 323, 693-693
0.18Citations (PDF)
190Is screening for breast cancer with mammography justifiable?
Lancet, The, 2000, 355, 129-134
62.1827Citations (PDF)
191Extracts from "Clinical Evidence": Non-steroidal anti-inflammatory drugs
BMJ: British Medical Journal, 2000, 320, 1058-1061
0.199Citations (PDF)
192Randomised clinical trials in the Scandinavian Journal of Rheumatology
Scandinavian Journal of Rheumatology, 2000, 29, 349-351
1.44Citations (PDF)
193Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
JAMA - Journal of the American Medical Association, 1999, 282, 1752
16.5112Citations (PDF)
194Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis
BMJ: British Medical Journal, 1998, 316, 811-818
0.1100Citations (PDF)
195House dust mite control measures in the management of asthma: meta-analysis
BMJ: British Medical Journal, 1998, 317, 1105-1110
0.1188Citations (PDF)
196Intermittent low dose prednisolone is safe in rheumatoid arthritis
BMJ: British Medical Journal, 1998, 316, 1606-1606
0.11Citations (PDF)
197Alternating Treatment with Didanosine and Zidovudine versus Either Drug Alone for the Treatment of Advanced HIV Infection. The Alter Study
Scandinavian Journal of Infectious Diseases, 1997, 29, 121-128
1.55Citations (PDF)
198The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta- analysis
European Journal of Clinical Pharmacology, 1997, 51, 389-393
2.040Citations (PDF)
199Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
BMJ: British Medical Journal, 1997, 314, 1238
0.1101Citations (PDF)
200Blinding during data analysis and writing of manuscripts
Contemporary Clinical Trials, 1996, 17, 285-290
2.8117Citations (PDF)
201Guidelines for treatment of hypertension
Lancet, The, 1995, 346, 1631
62.11Citations (PDF)
202Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis
BMJ: British Medical Journal, 1995, 310, 1495-1498
0.167Citations (PDF)
203Steroids and peptic ulcer: an end to the controversy?
Journal of Internal Medicine, 1994, 236, 599-601
7.316Citations (PDF)
204Meta-analysis of NSAIDs: Contribution of Drugs, Doses, Trial Designs, and Meta-analytic Techniques
Scandinavian Journal of Rheumatology, 1993, 22, 255-260
1.421Citations (PDF)
205Cimetidine suspension as adjuvant to energy restricted diet in treating obesity.
BMJ: British Medical Journal, 1993, 306, 1093-1096
0.123Citations (PDF)
206Cimetidine and weight loss
BMJ: British Medical Journal, 1993, 307, 446.4-447
0.10Citations (PDF)
207Trend towards Decreased Survival in Patients Infected with HIV Resistant to Zidovudine
Scandinavian Journal of Infectious Diseases, 1992, 24, 563-565
1.55Citations (PDF)
208Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit
Journal of Clinical Epidemiology, 1992, 45, 587-594
3.723Citations (PDF)
209Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy
Antiviral Research, 1992, 18, 303-316
3.812Citations (PDF)
210Isolation of HIV from cultures of purified CD4+ lymphocytes
Journal of Virological Methods, 1991, 35, 15-25
1.614Citations (PDF)
211Patients' views on the least acceptable increase in survival with zidovudine treatment
Scandinavian Journal of Infectious Diseases, 1991, 23, 509-510
1.53Citations (PDF)
212Sensitivity of effect variables in rheumatoid arthritis: A meta-analysis of 130 placebo controlled NSAID trials controlled NSAID trials
Journal of Clinical Epidemiology, 1990, 43, 1313-1318
3.782Citations (PDF)
213Multiple publication of reports of drug trials
European Journal of Clinical Pharmacology, 1989, 36, 429-432
2.099Citations (PDF)
214PATIENTS' PREFERENCE IN INDOMETHACIN TRIALS: AN OVERVIEW
Lancet, The, 1989, 333, 88-91
62.132Citations (PDF)
215Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis
Contemporary Clinical Trials, 1989, 10, 31-56
2.8302Citations (PDF)
216Double-Blind Study of Naproxen vs Placebo in the Treatment of Acute Migraine Attacks
Cephalalgia, 1989, 9, 29-32
4.122Citations (PDF)
217Steady State Pharmacokinetics of Naproxen in Elderly Rheumatics Compared with Young Volunteers
Scandinavian Journal of Rheumatology, 1988, 17, 11-16
1.412Citations (PDF)
218Condoms to Prevent HIV Transmission Do Not Imply Truly Safe Sex
Scandinavian Journal of Infectious Diseases, 1988, 20, 233-234
1.518Citations (PDF)
219Yield of Diagnostic Tests for Opportunistic Infections in AIDS: A Survey of 33 Patients
Scandinavian Journal of Infectious Diseases, 1988, 20, 395-402
1.57Citations (PDF)
220Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine
BMJ: British Medical Journal, 1988, 296, 820-822
0.136Citations (PDF)
221Reference bias in reports of drug trials.
BMJ: British Medical Journal, 1987, 295, 654-656
0.1188Citations (PDF)
222A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars
International Journal of Oral and Maxillofacial Surgery, 1986, 15, 389-394
2.123Citations (PDF)
223Somatostatin analogues for acute bleeding oesophageal varices
The Cochrane Library, 0, 2012,
2.163Citations (PDF)
224Placebo interventions for all clinical conditions
The Cochrane Library, 0, ,
2.1406Citations (PDF)
225General health checks in adults for reducing morbidity and mortality from disease
The Cochrane Library, 0, ,
2.1186Citations (PDF)
226Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia
The Cochrane Library, 0, ,
2.112Citations (PDF)
227“Adaptive pathways” to drug authorisation: adapting to industry?
BMJ, The, 0, , i4437
0.243Citations (PDF)
228Screening for reducing morbidity and mortality in malignant melanoma
The Cochrane Library, 0, ,
2.13Citations (PDF)
229Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports
BMJ, The, 0, , i65
0.2266Citations (PDF)
230Antidepressants are addictive and increase the risk of relapse
BMJ, The, 0, , i574
0.24Citations (PDF)
231Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
The Cochrane Library, 0, ,
2.15Citations (PDF)
232Financial conflicts of interest and outcomes and quality of systematic reviews
The Cochrane Library, 0, ,
2.15Citations (PDF)
233Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors
BMJ: British Medical Journal, 0, , k3654
0.157Citations (PDF)
234Challenges of independent assessment of potential harms of HPV vaccines
BMJ: British Medical Journal, 0, , k3694
0.115Citations (PDF)
235Office of NHS cancer screening programme misrepresents Nordic work in breast screening row
BMJ: British Medical Journal, 0, 323, 1131.2
0.10Citations (PDF)